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Abstract
Purpose. To describe successful palliation of a patient with metastatic adamantinoma presenting with lung metastases and
hypercalcemia resulting from a parathormone-like substance released from the tumor.
Methods and materials. The records of a patient with a history of a tibial adamantinoma who presented with symptoms of
hypercalcemia 20 years after the original surgery, as well as the literature concerning hypercalcemia and adamantinoma were
reviewed and summarized.
Results. After thorough review of the literature we found no prior reports of radiation being used for palliation of hypercal-
cemia associated with metastatic adamantinoma. We report rapid improvement in symptoms and normalization of serum
calcium levels following a course of radiation therapy.The patient remains asymptomatic 15 months following radiotherapy
despite a gradual return of elevated serum calcium levels.
Discussion. Radiation therapy should be considered as a palliative option for patients who are not surgical candidates
presenting with medically refractory hypercalcemia.
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Introduction
Adamantinoma is a rare tumor accounting for
approximately 0.1± 0.3% of primary bone tumors.
1,2
It is a slow growing tumor and tends to be locally
aggressive but rarely metastasizes.
3 The rate of
metastasis is approximately 15± 20% and usually
occurs in the ® rst two years following diagnosis.
4,5
The most common sites of metastases are bone, lung,
and regional lymph nodes.
4 Although many patients
with osteolytic bony metastases from other primary
tumors present with hypercalcemia it is unusual to
see hypercalcemia in patients with adamantinoma,
especially in the absence of bony disease. Here we
present a patient with an adamantinoma of the tibia
who subsequently developed lung metastases and
severe hypercalcemia.
Case report
A 39-year-old white male presented in 1973, at the
age of seventeen, with a left tibial mass. Biopsy
revealed an adamantinoma.The patient subsequently
underwent a below knee amputation. He did well
until 1993 when he started experiencing increasing
weakness and cough. Chest X-ray at that time revealed
bilateral pulmonary nodules. Biopsy of a left lung
nodule revealed metastatic adamantinoma. Magnetic
resonance imaging (MRI#)0 of the abdomen was
negative but images of the chest revealed a
heterogeneous soft tissue mass in the left hemithorax
enlarging the costophrenic sulcus, probably located in
the pleural space and contiguous with both the
diaphragm and visceral pleura of the paraspinal soft
tissue.There was also a 23 3 cm left anterior chest wall
mass and a right middle lobe nodule. The serum
calcium was 12.8 mg/dl (normal range 8.5± 10.5). He
underwent right upper lobectomy and wedge resection
of the right middle and lower lobes, con® rming
metastatic adamantinoma.This was followed by a wedge
resection of the left upper lobe that was negative for
neoplasm and resection of tissue adjacent to the aorta
which revealed metastatic adamantinoma.
The patient was seen in Radiation Oncology
following surgical resection;however,due to anticipated
high dose and large ® eld size requirements it was
thought that chemotherapy was a better option. He
received six cycles of chemotherapy with mesna, adri-
amycin, ifosfamide, and DTIC (MAID) with granu-
locyte colony-stimulating factor (G-CSF) and
interleukin-6 (IL-6) support from October 1993 to
February 1994. This was followed by six cycles of
carboplatin from June 1994 to December 1994.
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chronic tumor related hypercalcemia from April 1996
to December 1996 when computerized tomography
(CT) scan of the chest revealed a large soft tissue
mass in the left lower lobe of the lung involving the
diaphragm and extending into the abdomen lateral to
the spleen. There was rib involvement, displacement
of the heart and esophagus to the right, encasement
of the aorta and compression of the left atrium. At
that time the patient was complaining of rib pain,
dyspnea on exertion, fatigue and constant thirst. His
calcium was 15.2 mg/dl. He was tested for parathor-
mone related peptide and his serum level was elevated
at 9.6 pmol/l (normal range 0.0± 1.5).
The patient received radiation therapy to the left
hemithorax from February 1997 until March 1997.
This consisted of 45 Gy prescribed to the 98% isodose
line via left posterior oblique/left anterior oblique
® eld arrangement using 6 and 10 MV photons
delivered by a linear accelerator equipped with a
multi-leaf collimator. A partial transmission block
was effected by varying the leaf positions during treat-
ment to limit the dose to the left ventricle to 36 Gy.
We used a lung correction factor of 0.33.The patient
tolerated treatment well; however, he required a brief
hospitalization for atrial ® brillation and pericarditis
toward the end of the course. This resolved during
his hospital stay. The patient’s energy level increased
during the course of treatment and his calcium level
at completion was 11.5 mg/dl. The patient was able
to work full time as a high-level software developer
throughout the course of treatment. For 9 months
following treatment the patient’s calcium level
remained around the normal range; however, recently
this has started to increase with his last calcium being
14.0 mg/dl (June 1998; Fig. 1) He continues to work
full time and is without complaints 15 months
following completion of radiation.
Discussion
Adamantinoma (ameloblastoma) is a rare entity that
usually arises in the mandible but has been demon-
strated in other bones.This tumor is considered to be
low grade; however, it does tend to have a high local
recurrence rate if marginal surgery is performed.
6
There have been several reports of patients with lung
metastases that develop several years after the original
diagnosis.
7± 10 Since patients with metastatic disease
can still have prolonged survival, aggressive therapy
is often warranted.
Hypercalcemia is a common occurrence in cancer
patients. It can result from bone destruction from
metastatic disease or it may arise from tumoral secre-
tion of parathormone-like substances. In some of
these cases radiation therapy has been used sucess-
fully to control tumor-related hypercalcemia that is
refractory to other therapy.
11± 14
There are reports in the literature of patients with
metastatic ameloblastoma presenting with hypercal-
cemia; in these cases the hypercalcemia is often associ-
ated with high levels of a parathyroid-like hormone
circulating in the blood.
15Although this phenomenon
is often associated with metastatic disease, there have
been similar cases reported in which the primary
tumor was thought to be producing a parathyroid-
like substance. In one case, resection of the tumor led
to normalization of the serum calcium level.
16 Our
case demonstrates that radiation therapy can be used
as another modality to normalize elevated calcium
levels produced by metastatic adamantinoma and
should be considered as a palliative treatment option
in patients presenting with medically refractory hyper-
calcemia who are not surgical candidates.
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